IL-12p70 plasma levels correlate with aGVHD incidence and severity. (A) Kinetics of IL-12p70 secretion before RIC allo-SCT at the time of graft infusion (day 0) and in the first 3 months after RIC allo-SCT. Median levels and SEMs are shown for patients with (▴) grades 0 to I aGVHD and patients with (▪) grades II to IV aGVHD. (B) Correlation of IL-12p70 levels with aGVHD grade in the group of 75 patients in whom IL-12p70 was measured closely and rigorously before aGVHD clinical onset in the first month after RIC allo-SCT. (C) Peripheral blood monocyte recovery. (D) Naive CD3⁺CD4⁺CD45RA⁺CD27⁺ T lymphocyte recovery as measured in the group of 75 patients closely and rigorously before aGVHD clinical onset in the first month after RIC allo-SCT. As detailed in “Patients and methods,” plasma samples were collected according to a prespecified schedule applied to all patients during the entire study period. Data represent the same single time point analysis for all patients, not the maximum level for each patient within the first month. IL-12p70 levels were measured by standard ELISA. Monocytes were counted by an automated counter. Naive CD4⁺ T lymphocytes were identified by 4-color flow cytometry. Short horizontal lines indicate the median values.